Heartflow (NASDAQ:HTFL – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday, Wall Street Zen reports.
A number of other equities analysts have also recently issued reports on HTFL. UBS Group began coverage on shares of Heartflow in a research report on Wednesday, September 9th. They set a “neutral” rating and a $55.00 target price for the company. Piper Sandler reissued an “overweight” rating and set a $64.00 target price (up from $45.00) on shares of Heartflow in a research report on Tuesday, October 20th. Canaccord Genuity Group raised their price objective on shares of Heartflow from $45.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, September 22nd. Stifel Nicolaus increased their target price on Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Heartflow in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $48.62.
Check Out Our Latest Stock Report on HTFL
Heartflow Price Performance
Shares of NASDAQ:HTFL opened at $52.40 on Friday. The business’s 50 day moving average is $51.28 and its 200-day moving average is $34.64. Heartflow has a 1-year low of $20.13 and a 1-year high of $60.56.
Heartflow (NASDAQ:HTFL – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.15. The company had revenue of $64.08 million for the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%. The business’s revenue for the quarter was up 47.7% on a year-over-year basis. As a group, analysts anticipate that Heartflow will post -0.75 earnings per share for the current fiscal year.
Insider Activity
In other news, CEO John Farquhar sold 38,900 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $49.57, for a total value of $1,928,273.00. Following the completion of the transaction, the chief executive officer owned 283,014 shares in the company, valued at $14,029,003.98. This represents a 12.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Campbell Rogers sold 23,933 shares of the stock in a transaction dated Thursday, October 22nd. The shares were sold at an average price of $55.01, for a total transaction of $1,316,554.33. Following the completion of the sale, the insider owned 73,453 shares of the company’s stock, valued at approximately $4,040,649.53. This trade represents a 24.58% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 328,038 shares of company stock worth $15,490,354. Corporate insiders own 7.70% of the company’s stock.
Hedge Funds Weigh In On Heartflow
A number of institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC grew its position in Heartflow by 75.1% during the third quarter. GAMMA Investing LLC now owns 641 shares of the company’s stock worth $32,000 after buying an additional 275 shares during the period. Allworth Financial LP boosted its stake in Heartflow by 116.4% in the third quarter. Allworth Financial LP now owns 1,145 shares of the company’s stock worth $57,000 after purchasing an additional 616 shares in the last quarter. IFP Advisors Inc lifted its position in Heartflow by 844.7% in the 3rd quarter. IFP Advisors Inc now owns 803 shares of the company’s stock valued at $40,000 after acquiring an additional 718 shares in the last quarter. Strs Ohio boosted its holdings in Heartflow by 35.3% in the 1st quarter. Strs Ohio now owns 4,600 shares of the company’s stock valued at $112,000 after purchasing an additional 1,200 shares during the period. Finally, Integrated Wealth Concepts LLC bought a new position in shares of Heartflow in the 2nd quarter worth about $53,000.
Heartflow Company Profile
Heartflow, Inc is a medical technology company that develops artificial intelligence-based tools to help physicians diagnose and manage coronary artery disease. Its platform uses data from coronary computed tomography angiography (CCTA) scans to create personalized, three-dimensional models of a patient’s coronary arteries and provide noninvasive assessments of blood flow and disease.
The company’s products include Heartflow Analysis, which provides fractional flow reserve computed tomography (FFR-CT) evaluations to help identify potentially significant blockages, as well as tools for assessing coronary plaque and planning treatment.
See Also
- Five stocks we like better than Heartflow
- Q3 Earnings Have Investors Wondering: Is Mercado Libre Finally a Buy?
- CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop?
- Array and Shoals Are Merging: Who Really Wins the All-Stock Solar Deal?
- Duolingo’s User Growth Is Outpacing Bookings, But Is Its Strategy Paying Off?
Receive News & Ratings for Heartflow Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heartflow and related companies with MarketBeat.com's FREE daily email newsletter.
